These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21787450)

  • 1. Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome.
    Richard C; Couture P; Desroches S; Benjannet S; Seidah NG; Lichtenstein AH; Lamarche B
    Br J Nutr; 2012 Mar; 107(5):705-11. PubMed ID: 21787450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Mediterranean diet on plasma adipokine concentrations in men with metabolic syndrome.
    Richard C; Royer MM; Couture P; Cianflone K; Rezvani R; Desroches S; Lamarche B
    Metabolism; 2013 Dec; 62(12):1803-10. PubMed ID: 23993420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Mediterranean diet with and without weight loss on apolipoprotein B100 metabolism in men with metabolic syndrome.
    Richard C; Couture P; Ooi EM; Tremblay AJ; Desroches S; Charest A; Lichtenstein AH; Lamarche B
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):433-8. PubMed ID: 24265415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome.
    Richard C; Couture P; Desroches S; Lamarche B
    Obesity (Silver Spring); 2013 Jan; 21(1):51-7. PubMed ID: 23505168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the Mediterranean Diet before and after Weight Loss on Eating Behavioral Traits in Men with Metabolic Syndrome.
    Carbonneau É; Royer MM; Richard C; Couture P; Desroches S; Lemieux S; Lamarche B
    Nutrients; 2017 Mar; 9(3):. PubMed ID: 28335489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Mediterranean diet with and without weight loss on cardiovascular risk factors in men with the metabolic syndrome.
    Richard C; Couture P; Desroches S; Charest A; Lamarche B
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):628-35. PubMed ID: 20554173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an isoenergetic traditional Mediterranean diet on apolipoprotein A-I kinetic in men with metabolic syndrome.
    Richard C; Couture P; Desroches S; Lichtenstein AH; Lamarche B
    Nutr J; 2013 Jun; 12(1):76. PubMed ID: 24499022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?
    Chan DC; Lambert G; Barrett PH; Rye KA; Ooi EM; Watts GF
    Clin Chem; 2009 Nov; 55(11):2049-52. PubMed ID: 19713274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ; Lambert G; Dahlbäck B; Nielsen LB; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.